Revtopik Coverage Reaches 91% of U.S. Commercial and Medicare Lives
1 report, 1 independent
Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Coverage for Revtopik has reached 91% of U.S. commercial and Medicare lives. Since its commercial availability on September 30, 78% of the top 36 strategic accounts have ordered the drug, which represents approximately 50% of the total addressable patient population.
From fool.com
Why it matters
The high level of payer coverage reflects broad engagement with payers over the last 18 months. The addressable market for second-line treatment for HR-positive, HER2-negative advanced breast cancer is valued at $9 billion annually.
From fool.com
Who's involved
- MedicareUS federal health insurance program whose lives are covered by Revtopik
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Medicare
US federal health insurance